

TDMs No. 20011 - 06

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 10/01/2008

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

F1_M3

C Number: C20011
Lock Date: 06/15/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	6	13	9	9
Natural Death	7	4	9	5
Survivors				
Terminal Sacrifice	37	33	32	36
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Gallbladder	(40)	(40)	(34)	(38)
Intestine Large, Rectum	(45)	(48)	(43)	(48)
Intestine Small, Duodenum	(44)	(48)	(43)	(46)
Polyp Adenomatous	1 (2%)	1 (2%)		
Intestine Small, Jejunum	(44)	(48)	(43)	(46)
Carcinoma	4 (9%)	1 (2%)	1 (2%)	
Liver	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Hepatoblastoma	1 (2%)	1 (2%)	1 (2%)	
Hepatocellular Adenoma	16 (32%)	14 (28%)	19 (38%)	15 (30%)
Hepatocellular Adenoma, Multiple	14 (28%)	18 (36%)	14 (28%)	8 (16%)
Hepatocellular Carcinoma	9 (18%)	8 (16%)	15 (30%)	7 (14%)
Hepatocellular Carcinoma, Multiple	6 (12%)	7 (14%)	4 (8%)	4 (8%)
Hepatocholangiocarcinoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Hepatocholangiocarcinoma, Multiple				1 (2%)
Capsule, Carcinoma, Metastatic, Pancreas			1 (2%)	
Mesentery	(9)	(11)	(6)	(7)
Carcinoma, Metastatic, Pancreas	1 (11%)		1 (17%)	
Hepatocholangiocarcinoma, Metastatic, Liver				1 (14%)
Pancreas	(48)	(50)	(48)	(50)
Carcinoma	1 (2%)			
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Acinar Cell, Carcinoma			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Salivary Glands	(49)	(50)	(49)	(50)
Stomach, Forestomach	(47)	(50)	(48)	(50)
Squamous Cell Papilloma				2 (4%)
Stomach, Glandular	(47)	(49)	(47)	(49)
Tooth	(8)	(8)	(9)	(11)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(3)	(1)	(0)	(0)
Heart	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Carcinoma, Metastatic, Pancreas	1 (2%)			
Hemangiosarcoma		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)		1 (2%)	2 (4%)
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(50)	(49)	(50)
Adenoma	1 (2%)		1 (2%)	
Carcinoma, Metastatic, Pancreas			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Subcapsular, Adenoma	3 (6%)	3 (6%)	1 (2%)	
Adrenal Medulla	(50)	(49)	(49)	(50)
Pheochromocytoma Benign	1 (2%)		1 (2%)	
Pheochromocytoma Malignant				1 (2%)
Islets, Pancreatic	(48)	(50)	(48)	(50)
Adenoma		1 (2%)		1 (2%)
Pituitary Gland	(46)	(48)	(46)	(48)
Pars Distalis, Adenoma	1 (2%)	1 (2%)		
Thyroid Gland	(49)	(50)	(48)	(50)
GENERAL BODY SYSTEM				
Peritoneum	(0)	(0)	(1)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Carcinoma, Metastatic, Pancreas			1 (100%)	
GENITAL SYSTEM				
Coagulating Gland	(1)	(0)	(0)	(0)
Epididymis	(50)	(50)	(50)	(50)
Preputial Gland	(49)	(49)	(50)	(50)
Bilateral, Squamous Cell Carcinoma		1 (2%)		
Prostate	(49)	(50)	(48)	(50)
Seminal Vesicle	(48)	(50)	(49)	(50)
Adenoma	1 (2%)			
Hepatocolangiocarcinoma, Metastatic, Liver		1 (2%)		
Testes	(50)	(50)	(50)	(50)
Interstitial Cell, Adenoma				1 (2%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(48)	(48)	(48)	(50)
Hemangiosarcoma		1 (2%)		1 (2%)
Mast Cell Tumor Benign			1 (2%)	
Lymph Node	(1)	(1)	(3)	(0)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (33%)	
Lumbar, Carcinoma, Metastatic, Uncertain Primary Site			1 (33%)	
Popliteal, Carcinoma, Metastatic, Uncertain Primary Site			1 (33%)	
Lymph Node, Bronchial	(23)	(30)	(32)	(31)
Carcinoma, Metastatic, Pancreas			1 (3%)	
Hepatocellular Carcinoma, Metastatic, Liver		1 (3%)	1 (3%)	
Hepatocolangiocarcinoma, Metastatic, Liver		1 (3%)	1 (3%)	2 (6%)
Lymph Node, Mandibular	(27)	(28)	(21)	(26)
Lymph Node, Mediastinal	(35)	(32)	(35)	(34)
Carcinoma, Metastatic, Pancreas	1 (3%)		1 (3%)	
Hepatocellular Carcinoma, Metastatic, Liver		1 (3%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Hepatocholangiocarcinoma, Metastatic, Liver	1 (3%)	1 (3%)	1 (3%)	2 (6%)
Lymph Node, Mesenteric Carcinoma, Metastatic, Pancreas	(48)	(46)	(44)	(48)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	1 (2%)	1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Spleen	(48)	(50)	(49)	(50)
Hemangiosarcoma	2 (4%)	1 (2%)		
Mast Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Thymus	(38)	(35)	(37)	(32)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (3%)	1 (3%)		
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Subcutaneous Tissue, Fibrous Histiocytoma				1 (2%)
Subcutaneous Tissue, Hemangiosarcoma		1 (2%)	1 (2%)	
Subcutaneous Tissue, Sarcoma			1 (2%)	
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(49)	(50)	(50)
Hemangiosarcoma				1 (2%)
Osteosarcoma	1 (2%)			
Skeletal Muscle	(0)	(2)	(1)	(2)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (100%)	
Hemangiosarcoma				1 (50%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (50%)		1 (50%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
NERVOUS SYSTEM				
Brain	(50)	(50)	(49)	(50)
RESPIRATORY SYSTEM				
Larynx	(48)	(50)	(48)	(50)
Lung	(50)	(50)	(49)	(49)
Alveolar/Bronchiolar Adenoma	6 (12%)	4 (8%)	4 (8%)	4 (8%)
Alveolar/Bronchiolar Adenoma, Multiple		1 (2%)		1 (2%)
Alveolar/Bronchiolar Carcinoma	8 (16%)	7 (14%)	8 (16%)	9 (18%)
Alveolar/Bronchiolar Carcinoma, Multiple			2 (4%)	1 (2%)
Carcinoma, Metastatic, Harderian Gland			1 (2%)	
Carcinoma, Metastatic, Pancreas	1 (2%)		1 (2%)	
Hemangiosarcoma, Metastatic, Liver			1 (2%)	
Hemangiosarcoma, Metastatic, Spleen	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	7 (14%)	10 (20%)	12 (24%)	4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Osteosarcoma, Metastatic, Uncertain Primary Site		1 (2%)		
Bronchiole, Adenoma		1 (2%)		
Nose	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Pleura	(0)	(0)	(1)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (100%)	
Hepatocholangiocarcinoma, Metastatic, Liver				1 (100%)
Trachea	(49)	(50)	(47)	(50)
SPECIAL SENSES SYSTEM				
Eye	(45)	(47)	(44)	(47)
Harderian Gland	(46)	(49)	(49)	(48)
Adenoma	6 (13%)	3 (6%)	2 (4%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Carcinoma Hepatocolangiocarcinoma, Metastatic, Liver Bilateral, Adenoma	3 (7%) 1 (2%)	1 (2%)	7 (14%)	5 (10%) 1 (2%)
URINARY SYSTEM				
Kidney Alveolar/Bronchiolar Carcinoma, Metastatic, Lung Hepatocellular Carcinoma, Metastatic, Liver Hepatocolangiocarcinoma, Metastatic, Liver Urethra Urinary Bladder	(49) 1 (2%) (0) (47)	(50) 1 (2%) 1 (2%) (0) (50)	(50) 1 (2%) 1 (2%) (0) (47)	(49) 2 (4%) (1) (48)
SYSTEMIC LESIONS				
Multiple Organs Histiocytic Sarcoma Lymphoma Malignant	*(50) 2 (4%)	*(50) 2 (4%)	*(50) 1 (2%) 3 (6%)	*(50)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Tumor Summary for Males				
Total Animals with Primary Neoplasms (b)	47	47	46	36
Total Primary Neoplasms	90	81	90	69
Total Animals with Benign Neoplasms	36	35	35	29
Total Benign Neoplasms	51	47	43	35
Total Animals with Malignant Neoplasms	30	29	34	24
Total Malignant Neoplasms	39	34	47	34
Total Animals with Metastatic Neoplasms	9	12	17	6
Total Metastatic Neoplasms	18	24	39	21
Total Animals with Malignant Neoplasms Uncertain Primary Site		2	1	
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	10	7	8	8
Natural Death	4	3	5	
Survivors				
Moribund Sacrifice	1			1
Terminal Sacrifice	35	40	37	41
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma	1 (2%)			
Gallbladder	(43)	(36)	(36)	(44)
Intestine Large, Cecum	(48)	(49)	(46)	(50)
Leiomyoma		1 (2%)	1 (2%)	
Intestine Large, Colon	(48)	(49)	(46)	(50)
Leiomyoma			1 (2%)	
Intestine Large, Rectum	(47)	(49)	(46)	(50)
Intestine Small, Duodenum	(46)	(49)	(46)	(50)
Hepatoblastoma, Metastatic, Liver				1 (2%)
Intestine Small, Ileum	(48)	(49)	(46)	(50)
Hemangiosarcoma		1 (2%)		
Intestine Small, Jejunum	(46)	(49)	(46)	(50)
Hemangiosarcoma		1 (2%)		
Leiomyosarcoma				1 (2%)
Liver	(50)	(50)	(50)	(50)
Hemangiosarcoma				1 (2%)
Hepatoblastoma			1 (2%)	
Hepatocellular Adenoma	13 (26%)	8 (16%)	13 (26%)	9 (18%)
Hepatocellular Adenoma, Multiple	6 (12%)	5 (10%)	2 (4%)	3 (6%)
Hepatocellular Carcinoma	5 (10%)	4 (8%)	7 (14%)	
Hepatoblastoma				1 (2%)
Mesentery	(11)	(9)	(11)	(13)
Hemangiosarcoma	1 (9%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Hepatocholangiocarcinoma, Metastatic, Liver				1 (8%)
Pancreas	(50)	(49)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(49)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Squamous Cell Papilloma				2 (4%)
Stomach, Glandular	(50)	(49)	(48)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum				1 (2%)
Tongue	(0)	(0)	(1)	(0)
Squamous Cell Carcinoma			1 (100%)	
Tooth	(0)	(1)	(0)	(0)
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Adrenal Medulla	(50)	(50)	(49)	(50)
Pheochromocytoma Benign	3 (6%)		2 (4%)	
Pheochromocytoma Malignant	1 (2%)			
Islets, Pancreatic	(50)	(49)	(49)	(49)
Carcinoma		1 (2%)		
Pituitary Gland	(46)	(49)	(47)	(48)
Pars Distalis, Adenoma	5 (11%)	7 (14%)	5 (11%)	9 (19%)
Pars Distalis, Carcinoma	1 (2%)			
Pars Intermedia, Adenoma			4 (9%)	
Thyroid Gland	(49)	(50)	(46)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
GENERAL BODY SYSTEM				
Peritoneum	(0)	(0)	(0)	(1)
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum				1 (100%)
GENITAL SYSTEM				
Ovary	(50)	(50)	(50)	(49)
Cystadenoma	3 (6%)	1 (2%)	1 (2%)	2 (4%)
Granulosa Cell Tumor Benign			1 (2%)	
Granulosa Cell Tumor Malignant		1 (2%)		
Luteoma	1 (2%)		1 (2%)	
Uterus	(50)	(50)	(50)	(50)
Carcinoma		1 (2%)		
Choriocarcinoma, Metastatic, Uncertain Primary Site		1 (2%)		
Leiomyosarcoma				1 (2%)
Polyp Stromal		2 (4%)	2 (4%)	3 (6%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(49)	(50)
Lymph Node	(6)	(5)	(3)	(8)
Lymph Node, Bronchial	(37)	(32)	(39)	(34)
Hepatocholangiocarcinoma, Metastatic, Liver				1 (3%)
Lymph Node, Mandibular	(45)	(30)	(30)	(37)
Lymph Node, Mediastinal	(45)	(39)	(41)	(37)
Hemangiosarcoma			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver				1 (3%)
Lymph Node, Mesenteric	(48)	(47)	(47)	(49)
Spleen	(50)	(49)	(50)	(50)
Hemangiosarcoma	1 (2%)	1 (2%)	1 (2%)	
Thymus	(49)	(45)	(45)	(45)
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Thymoma Benign			1 (2%)	
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Adenosquamous Carcinoma			1 (2%)	2 (4%)
Carcinoma	2 (4%)			1 (2%)
Skin	(50)	(50)	(50)	(50)
Sebaceous Gland, Carcinoma			1 (2%)	
Subcutaneous Tissue, Fibrosarcoma			1 (2%)	
Subcutaneous Tissue, Fibrous	1 (2%)	2 (4%)		
Histiocytoma				
Subcutaneous Tissue, Hemangioma		1 (2%)		
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)			
Subcutaneous Tissue, Sarcoma	7 (14%)	2 (4%)	3 (6%)	1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			
Skeletal Muscle	(0)	(0)	(0)	(1)
Hepatocolangiocarcinoma, Metastatic, Liver				1 (100%)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pituitary Gland	1 (2%)			
Meningioma Benign			1 (2%)	
Peripheral Nerve	(1)	(1)	(1)	(1)
Spinal Cord	(1)	(1)	(1)	(1)
RESPIRATORY SYSTEM				
Larynx	(50)	(50)	(50)	(50)
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)	6 (12%)	4 (8%)	8 (16%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Alveolar/Bronchiolar Adenoma, Multiple				2 (4%)
Alveolar/Bronchiolar Carcinoma		5 (10%)	4 (8%)	3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple		2 (4%)	1 (2%)	1 (2%)
Choriocarcinoma, Metastatic, Uterus		1 (2%)		
Hepatoblastoma, Metastatic, Liver			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Sarcoma, Metastatic, Skin	1 (2%)			
Bronchiole, Adenoma		1 (2%)		1 (2%)
Nose	(50)	(50)	(50)	(50)
Pleura	(0)	(0)	(1)	(0)
Trachea	(50)	(49)	(50)	(50)
SPECIAL SENSES SYSTEM				
Eye	(47)	(49)	(45)	(50)
Harderian Gland	(49)	(49)	(48)	(50)
Adenoma	3 (6%)	2 (4%)	4 (8%)	2 (4%)
Carcinoma	2 (4%)	1 (2%)		1 (2%)
Zymbal's Gland	(0)	(1)	(0)	(0)
Carcinoma		1 (100%)		
URINARY SYSTEM				
Kidney	(50)	(49)	(49)	(50)
Hepatoblastoma, Metastatic, Liver			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Urinary Bladder	(50)	(49)	(48)	(50)
Hemangiosarcoma	1 (2%)			
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)		2 (4%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
Lymphoma Malignant	17 (34%)	9 (18%)	15 (30%)	11 (22%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

1-Bromopropane

Time Report Requested: 09:42:38

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 106-94-5

First Dose M/F: 07/21/03 / 07/21/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	62.5 PPM	125 PPM	250 PPM
--------------------	---------	----------	---------	---------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	42	37	43	34
Total Primary Neoplasms	79	66	82	67
Total Animals with Benign Neoplasms	22	24	30	28
Total Benign Neoplasms	35	34	43	41
Total Animals with Malignant Neoplasms	33	27	32	22
Total Malignant Neoplasms	44	32	39	26
Total Animals with Metastatic Neoplasms	2	2	2	2
Total Metastatic Neoplasms	2	3	3	14
Total Animals with Malignant Neoplasms Uncertain Primary Site		1	1	
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors